Leading Out of Silos: The Suite Spot

The Suite Spot is a fireside chat about all topics IT and OT. We will attempt to bring clarity to the business value of traditionally tech topics. We remove the fog of acronym war and deliver to you the value you need to make these complex technologies work for your business.

Powered by RedCircle

Carlos Vargas, host of The Suite Spot, was joined with co-hosts Howard Holton and Paul Lewis in a discussion on the possibilities of AI. Is the world ready for AI to capture and become the human experience? Not yet, and neither is the technology. It’s the romanticized, big-screen perspective of AI that many visualize. But AI is instrumental in so many aspects of human life, just not to that degree.

Paul said, “The conversation of synthetic humans is far away. It’s because data science can’t be applied to people. They are messy. They are individuals. People are unpredictable and have free will. At this point, data science will stick to objects that are engineered to provide data.”

Is AI’s impact on human behavior viable? It would require lots of data and computing power. But what about what AI can do now as it interacts with humans?

Howard argued, “Yes, you’re correct that AI can’t know 100% of the time how a human is going to react. But that’s not really the goal of AI. Right now, with the right data and algorithms, you can target an audience to capture about 80%. AI has first to understand people before it can recreate them.”

The discussion of AI and its impact on humans might be around the replaceability of humans in a scenario like driverless cars.

Howard said, “Automated cars will be better drivers than people in 5 years, but humans won’t be comfortable with automated cars for 15 years. The car has to be autonomous by itself. It can feed data back on how to make the care better at its job. The decision-making process should be self-contained. The human problem is that we think we’re better decision-makers, but we’re not.”

If AI can replace drivers, what other roles are possible. Could AI be a better lawyer? Howard commented, “Most lawyers never appear in court. A computer is good at many things attorneys do, but it can’t argue in front of a jury. An empathetic reaction isn’t possible. AI on a computer could listen to what happens in court and recommend arguments.”

Paul added, “This is more augmented and assisted AI, which is what we’re seeing now.

Make Sure to Subscribe to The Suite Spot to Stay Up to Date!

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More